Urokinase can reduce heparin dose in patients with hypercoagulable states during hemodialysis

References

• Ouseph R, Brier ME, Ward RA. Improved dialyzer reuse after use of a population pharmacodynamic model to determine heparin doses. Am J Kidney Dis. 2000;35(1):89–94
   PubMedGoogle Scholar
• Sonawane S, Kasbekar N, Berns JS. The safety of heparins in end-stage renal disease. Sem Dial. 2006;19(4):305–310
   PubMedGoogle Scholar
• Bharadwaj J, Jayaraman C, Shrivastava R. Heparin resistance. Lab Hematol. 2003;9(3):125–131
   PubMedGoogle Scholar
• Lo DS, Rabbat CG, Clase CM. Thromboembolism and anticoagulant management in hemodialysis patients: A practical guide to clinical management. Thromb Res. 2006;118(3):385–395
   PubMedGoogle Scholar
• Webb A, Abdalla M, Russell GI. A protocol of urokinase infusion and warfarin for the management of the thrombosed hemodialysis catheter. Nephrol Dial Transplant. 2001;16(10):2075–2078
   PubMedGoogle Scholar
• Guillet B, Simon N, Sampol JJ, et al. Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in hemodialysis. Nephrol Dial Transplant. 2003;18(11):2348–2353
   PubMedGoogle Scholar
• Farooq V, Hegarty J, Chandrasekar T, et al. Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. Am J Kidney Dis. 2004;43(3):531–537
   PubMed Web of Science ®Google Scholar
• Schetz M. Anticoagulation for continuous renal replacement therapy. Curr Opin Anaesthesiol. 2001;14(2):143–149
   PubMedGoogle Scholar
• Davenport A. Anticoagulation options for intermittent hemodialysis. Minerva Urol Nefrol. 2006;58(2):171–180
   PubMedGoogle Scholar
• Sagedal S, Hartmann A, Osnes K, et al. Intermittent saline flushes during hemodialysis do not alleviate coagulation and clot formation in stable patients receiving reduced doses of dalteparin. Nephrol Dial Transplant. 2006;21(2):444–449
   PubMedGoogle Scholar
• De Vos J, Hombrouckx R. Citrate anticoagulation and adverse events. EDTNA/ERCA J. 2003;29(3):112–113, 117
   PubMedGoogle Scholar
• Apsner R, Gruber D, Horl WH, Sunder-Plassmann G. Parathyroid hormone secretion during citrate anticoagulated hemodialysis in acutely ill maintenance hemodialysis patients. Anesth Analg. 2004;99(4):1199–1204, table of contents
   PubMedGoogle Scholar
• Balik M, Waldauf P, Plasil P, Pachl J. Prostacyclin versus citrate in continuous hemodiafiltration: An observational study in patients with high risk of bleeding. Blood Purif. 2005;23(4):325–329
   PubMedGoogle Scholar
• Ferguson LM, Dreisbach AW, Csongradi E, Juncos LA, Fulop T. Recurring extracorporeal circuit clotting during continuous renal replacement therapy in fungal sepsis: Successful treatment with argatroban. Am J Med Sci. 2013;345(3):256–258
   PubMedGoogle Scholar
• Tang IY, Cox DS, Patel K, et al. Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann Pharmacother. 2005;39(2):231–236
   PubMedGoogle Scholar
• Ward RA. Heparinization for routine hemodialysis. Adv Renal Replace Ther. 1995;2(4):362–370
   PubMedGoogle Scholar
• Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: An analysis of error. J Am Soc Nephrol. 1993;4(5):1205–1213
   PubMed Web of Science ®Google Scholar
• Ziai F, Benesch T, Kodras K, Neumann I, Dimopoulos-Xicki L, Haas M. The effect of oral anticoagulation on clotting during hemodialysis. Kidney Int. 2005;68(2):862–866
   PubMedGoogle Scholar
• Reiner JS, Coyne KS, Lundergan CF, C B. Superiority of bedside partial thromboplastin time to activated clotting time in controlling heparin anticoagulation. J Am Coll Cardiol. 1993;21:773–771
   Google Scholar
• Eiswirth G, Walch S, Bommer J. New bedside test for monitoring anticoagulation during hemodialysis. Artif Organs. 1998;22(4):346–348
   PubMedGoogle Scholar
• Ward RA. Effects of hemodialysis on coagulation and platelets: Are we measuring membrane biocompatibility? Nephrol Dial Transplant. 1995;10(Suppl 10):12–17
   PubMedGoogle Scholar
• Bonomini M, Dottori S, Amoroso L, Arduini A, Sirolli V. Increased platelet phosphatidylserine exposure and caspase activation in chronic uremia. J Thromb Hemost. 2004;2(8):1275–1281
   Google Scholar
• Kaw D, Malhotra D. Platelet dysfunction and end-stage renal disease. Semin Dialysis. 2006;19(4):317–322
   PubMedGoogle Scholar
• Hafner G, Swars H, Ehrenthal W, Schinzel H, Weilemann LS, Prellwitz W. The control of anti-coagulation in acute dialyses with sensitive laboratory parameters. Scand J Clin Lab Invest. 1992;52(4):289–296
   PubMed Web of Science ®Google Scholar
• Knapik P, Ciesla D, Przybylski R, Knapik T. The influence of heparin resistance on postoperative complications in patients undergoing coronary surgery. Med Sci Monit. 2012;18(2):CR105–111
   PubMedGoogle Scholar